Where CIDP treatment is heading

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease in which the immune system strips the insulation from nerves, causing weakness and numbness in the arms and legs that builds over months. A few thousand Americans are diagnosed each year. Immunoglobulin infusions, steroids and plasma exchange help most people but often must continue for years. Efgartigimod, an FcRn blocker, became the first new type of treatment in 2024, and drugs that block complement are in phase 3.

• 37studies open or running
• 10phase 3 trials
• 279papers published this year
• 3NIH-funded projects

1. Now

   Nov 2026

   A new type of treatmentHappened 61% lower relapse risk

   Efgartigimod cut relapse risk by 61% vs placebo among responders; FDA approved June 2024.

   61%: lower risk of relapse than with placebo.

   • ADHERE trial (efgartigimod)

   Not every drug worksHappened 63.2% worsened with rituximab

   Rituximab (63.2% vs 66.6% worsened) and rozanolixizumab did not beat placebo; riliprubart was stopped in refractory CIDP.

   63.2%: worsened by month 12 with rituximab, vs 66.6% with placebo.

   • Rituximab randomized trial
   • Rozanolixizumab phase 2
   • MOBILIZE trial (riliprubart)

2. 6 months

   by May 2027

   A second FcRn blockerPossible 61% lower relapse (efgartigimod)

   Janssen's nipocalimab ARISE trial (201 people) finishes December 2026.

   61%: lower risk of relapse than with placebo.

   • ADHERE trial (efgartigimod)
   • ARISE

3. 12 months

   by Nov 2027

   Complement blocker vs immunoglobulinPossible

   Sanofi's VITALIZE (160 people) compares riliprubart with IVIg; due July 2027.

   • MOBILIZE trial (riliprubart)
   • VITALIZE

   A C2-blocking antibodyPossible

   argenx's empasiprubart is in two phase 3 trials, one against IVIg (due September 2027) and one against placebo (October 2027).

   • EMVIGORATE
   • EMNERGIZE

4. 3 years

   by late 2029

   More complement blockersPossible

   Dianthus' claseprubart CAPTIVATE (256 people, due December 2028) and Immunovant's imeroprubart (162 people, due August 2028).

   • CAPTIVATE
   • Imeroprubart trial

5. 5 years

   by late 2031

   Coming off immunoglobulinLong shot

   The Dutch ReCIX trial (100 people) tests whether rituximab helps people achieve remission; due October 2027, with longer follow-up.

   • ReCIX

The research paths

Borrowed from other conditions

Open to join now

• CIDP on immunoglobulin

  Riliprubart vs IVIg

  Phase 3 · 134 sites

  Locations and eligibility →

• CIDP

  Empasiprubart vs IVIg

  Phase 3 · 107 sites

  Locations and eligibility →

• CIDP

  Empasiprubart vs placebo

  Phase 3 · 94 sites

  Locations and eligibility →

• CIDP

  Claseprubart

  Phase 3 · 201 sites

  Locations and eligibility →

• CIDP

  Nipocalimab

  Phase 2/3 · 120 sites

  Locations and eligibility →

See every recruiting CIDP trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

What just happened

Standard treatment today

• New diagnosisIV immunoglobulin, steroids or plasma exchange.
• MaintenanceIV or subcutaneous immunoglobulin, or efgartigimod injections; periodic trials of tapering.
• Not respondingCheck diagnosis (including nodal antibodies); rituximab for antibody-positive forms; clinical trials.
• RemissionGradual tapering of treatment with close monitoring.

See CIDP trials recruiting now →